论文部分内容阅读
目的 研究ｍｄｒｌ 基因表达与临床化疗的关系。方法 选择４４ 例白血病患者和５ 例正常对照者，运用ＲＴＰＣＲ方法检测ｍｄｒｌ 基因表达，同时评估患者对化疗的反应。结果 白血病患者初治组ｍｄｒｌ 阳性表达率为７８．９％ ，缓解组为５５ ．６ ％ ，难治复发组为９３ ．３ ％ ，对照组无一人表达；ｍｄｒｌ 阴性及低度表达者中有８２ ．４ ％的人达到ＣＲ，而ｍｄｒｌ 中、高度表达者中仅３７．０％ 的人达到ＣＲ（ Ｐ＝ ０ ．００３） 。结论 ｍｄｒｌ 基因表达增高与化疗耐药有关，可作为监测病情和判断预后的一个辅助指标。
Objective To study the relationship between mdrl gene expression and clinical chemotherapy. Methods 44 patients with leukemia and 5 normal controls were selected and RT-PCR was used to detect the expression of mdrl gene. At the same time, patients’ response to chemotherapy was evaluated. Results The positive expression rate of mdrl was 78.9% in the untreated patients with leukemia and 55 in the remission group. 6 % of the relapsed group was 93. At 3%, no one in the control group expressed; 82% of the mdrl-negative and low-level expression. 4% achieved CR, while only 37.0% of mdrl and highly expressed individuals achieved CR (P = 0.003). Conclusion The increased expression of mdrl gene is associated with chemotherapy resistance and can be used as an auxiliary index to monitor the condition and determine the prognosis.